BerGenBio ASA

Norwegian clinical stage biopharmaceutical company in Bergen, founded in 2007 out of research at the University of Bergen and listed on the Oslo Stock Exchange. Develops medicines that block the AXL receptor tyrosine kinase, whose activity is linked to treatment resistance, immune evasion and spread of disease, with the selective oral inhibitor bemcentinib as its lead candidate studied in cancers including lung cancer and leukaemia and in other aggressive conditions, and works with academic and industry partners on biomarker driven development.